Esperion Therapeutics (ESPR) CEO sells shares to pay RSU taxes

Rhea-AI Filing Summary

Esperion Therapeutics’ President and CEO Sheldon L. Koenig reported an open-market sale of 25,578 shares of common stock at $2.719 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from vested restricted stock units.

After this transaction, Koenig directly holds 2,172,699 shares of Esperion Therapeutics common stock. This filing reflects a tax-related disposition rather than a discretionary reduction of his overall shareholding.

Insider Trade Summary

Net Seller: 25,578 shares ($69,547)

Net Sell 1 txn

Insider Koenig Sheldon L.

Role President and CEO

Sold 25,578 shs ($70K)

Type	Security	Shares	Price	Value
Sale	Common Stock	25,578	$2.719	$70K

Holdings After Transaction: Common Stock — 2,172,699 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Koenig Sheldon L.

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MICHIGAN 48108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S		25,578(1)	D	$2.719	2,172,699	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Remarks:

	/s/ Sheldon L. Koenig	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Esperion Therapeutics (ESPR) CEO Sheldon Koenig report in this Form 4?

Sheldon Koenig reported selling 25,578 shares of Esperion common stock at $2.719 per share. The filing states the sale was conducted to cover tax obligations from recently vested restricted stock units.

Why did Esperion Therapeutics CEO sell 25,578 ESPR shares?

The shares were sold to satisfy tax obligations triggered by vested restricted stock units. This type of tax-related sale is typically mechanistic, reflecting required tax payments rather than a discretionary change in the CEO’s investment stance.

How many Esperion Therapeutics shares does the CEO hold after this transaction?

Following the reported sale, Sheldon Koenig directly holds 2,172,699 shares of Esperion Therapeutics common stock. This indicates that the 25,578 shares sold for tax obligations represent a relatively small portion of his total direct holdings.

At what price were the Esperion Therapeutics shares sold by the CEO?

The 25,578 shares of Esperion common stock were sold at $2.719 per share. This price is specifically disclosed in the insider trading report and applies to the tax-related sale connected to vested restricted stock units.

Is the Esperion CEO’s share sale described as open-market or private?

The transaction is classified as an open-market sale of common stock. The filing characterizes it as a sale executed to meet tax obligations associated with vested restricted stock units, rather than a discretionary portfolio adjustment.

Does this Esperion Therapeutics insider sale involve any derivative securities?

The reported transaction involves only common stock and no derivative securities. The filing also shows no remaining derivative positions in the derivative summary, emphasizing the event as a straightforward tax-related sale of common shares.